Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Blood Advances|July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysisNausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.
Blood Advances|February 26, 2026
Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort StudyJohn Sharp, Paolo Strati, Subodh Bhatta, et al.
American Journal of Hematology|July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab eraReem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
European Journal of Haematology|May 11, 2021
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survivalKrithika Shanmugasundaram, Subir Goyal, Jeffery Switchenko, et al.
Blood Advances|November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC ConsortiumJohn Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood Advances|September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A Bond, Jeffrey M Switchenko, Diego Villa, et al.
Blood Advances|December 14, 2022
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphomaNarendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, et al.
Blood Advances|May 28, 2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTRKitsada Wudhikarn, Megan M Herr, Min Chen, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Pageof 5